Seltorexant (MIN-202) reaches primary and critical secondary endpoint in Phase 2b clinical trials for insomnia patients

today, Minervacompany(http:// announcedthat the company's joint development with Janssen,""min-202" reached the primary and critical secondary endpoint sydd of the trial in the phase 2b clinicaltrial(http://for patients with insomnia, significantly accelerating sleep time for insomniacs and reducing the time patients wake up to sleepAbout Seltorexant
Seltorexant is a potential "first-in-class" receptor-specific antagonist for insomniaThe brain's appetite system is associated with a variety of physiological functions, including metabolism, stress response and wakefulnessIn insomnia patients and some patients with mood disorders, this system can lead to excessive awakeningBy suppressing this system, Seltorexant may relieve the patient's symptomsstudies
365 patients received different doses of seltorexant, different doses of zolpidem, and placebo treatment in a multicenter 2b clinical trial with randomized double-blindness, including placebo-controlled and active-controlledThe main therapeutic endpoint of the trial was the time it took for patients to reach lasting sleep on the first night of treatment (latency to persistent sleep, LPS)critical secondary endpoints include waking up within 6 hours of falling asleep (Wake After Sleep onset over first hours 6, WASO-6) and safety and tolerance indicatorsThe results showed that seltorexant provided statistically significant (p.001) and clinically significant improvements in LPS indicators compared to placebosOn the first night of treatment, seltorexant was able to reduce the average LPS by 50 minutes (10 mg dose) or 48 minutes (20 mg dose) for the placebo group for 15 minutesAt the same time, seltorexant was able to reduce WASO-6 time by 43 minutes (10 mg dose) or 45 minutes (20 mg dose) for the placebo group for 15 minutesSeltorexant (20 mg dose) also outperformed the active control group (p0.010) for the first night of LPS